Specific antibodies protect gamma-irradiated mice against Francisella tularensis infection

Microbial Pathogenesis

Volumn 53, Issue 5-6, 2012, Pages 259-268

  Kubelkova, Klara ^a   Krocova, Zuzana ^a   Balonova, Lucie ^a   Pejchal, Jaroslav ^a   Stulik, Jiri ^a   Macela, Ales ^a  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Cytokines; F. tularensis; Gamma irradiation; Protection; Specific antibodies

Indexed keywords

BACTERIUM ANTIBODY; FRANCISELLA TULARENSIS ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; LIVE VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL LOAD; BACTERIAL STRAIN; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRANCISELLA TULARENSIS; GAMMA IRRADIATION; HUMORAL IMMUNITY; IMMUNIZATION; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; SURVIVAL; TULAREMIA;

ANIMALS; ANTIBODIES, BACTERIAL; DISEASE MODELS, ANIMAL; FEMALE; FRANCISELLA TULARENSIS; GAMMA RAYS; HUMANS; IMMUNIZATION, PASSIVE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; SURVIVAL ANALYSIS; TULAREMIA;

ANIMALIA; BACTERIA (MICROORGANISMS); FRANCISELLA; FRANCISELLA TULARENSIS; FRANCISELLA TULARENSIS SUBSP. HOLARCTICA; FRANCISELLA TULARENSIS SUBSP. TULARENSIS; MUS;

EID: 84867397421     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2012.07.006     Document Type: Article

References (40)

1. Kugeler K.J., Mead P.S., Janusz A.M., Staples J.E., Kubota K.A., Chalcraft L.G. Molecular epidemiology of Francisella tularensis in the United States. Clinical Infectious Diseases 2009, 48:863-870.
2. Dienst F.T. Tularemia: a perusal of three hundred thirty-nine cases. Journal of the Louisiana State Medical Society 1963, 115:114-127.
3. Staples J.E., Kubota K.A., Chalcraft L.G., Mead P.S., Petersen J.M. Epidemiologic and molecular analysis of human tularemia, United States, 1964-2004. Emerging Infectious Diseases 2006, 12:1113-1118.
4. Eigelsbach H.T., Downs C.M. Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. Journal of Immunology 1961, 87:415-425.
5. Burke D.S. Immunization against tularemia: analysis of the effectiveness of live Francisella tularensis vaccine in prevention of laboratory-acquired tularemia. Journal of Infectious Diseases 1977, 135:55-60.
6. Elkins K.L., Rhinehart-Jones T.R., Culkin S.J., Yee D., Winegar R.K. Minimal requirements for murine resistance to infection with Francisella tularensis LVS. Infection and Immunity 1996, 64:3288-3293.
7. Yee D., Rhinehart-Jones T.R., Elkins K.L. Loss of either CD4+ or CD8+ T cells does not affect the magnitude of protective immunity to an intracellular pathogen, Francisella tularensis strain LVS. Journal of Immunology 1996, 157:5042-5048.
8. Elkins K.L., Bosio C.M., Rhinehart-Jones T.R. Importance of B cells, but not specific antibodies, in primary and secondary protective immunity to the intracellular bacterium Francisella tularensis live vaccine strain. Infection and Immunity 1999, 67:6002-6007.
9. Kirimanjeswara G.S., Golden J.M., Bakshi C.S., Metzger D.W. Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. Journal of Immunology 2007, 179:532-539.
10. Lu Z., Roche M.I., Hui J.H., Unal B., Felgner P.L., Gulati S. Generation and characterization of hybridoma antibodies for immunotherapy of tularemia. Immunology Letters 2007, 112:92-103.
11. Lavine C.L., Clinton S.R., Angelova-Fischer I., Marion T.N., Bina X.R., Bina J.E. Immunization with heat-killed Francisella tularensis LVS elicits protective antibody-mediated immunity. European Journal of Immunology 2007, 37:3007-3020.
12. Drabick J.J., Narayanan R.B., Williams J.C., Leduc J.W., Nacy C.A. Passive protection of mice against lethal Francisella tularensis (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine. The American Journal of the Medical Sciences 1994, 308:83-87.
13. Stenmark S., Lindgren H., Tärnvik A., Sjöstedt A. Specific antibodies contribute to the host protection against strains of Francisella tularensis subspecies holarctica. Microbial Pathogenesis 2003, 35:73-80.
14. Rhinehart-Jones T.R., Fortier A.H., Elkins K.L. Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells. Infection and Immunity 1994, 62:3129-3137.
15. Hale W.M., Stoner V.R. Effects of ionizing radiation on immunity. Radiation Research 1954, 1:459-469.
16. Russell E.S., Neufeld E.F., Higgins C.T. Comparison of normal blood picture of young adults from 18 inbred strains of mice. Proceedings of the Society for Experimental Biology and Medicine 1951, 78:761-766.
17. Grahn D. Acute radiation response of mice from a cross between radiosensitive and radioresistant strains. Genetics 1958, 43:835-843.
18. Grahn D., Hamilton K.F. Genetic variation in the acute lethal response of four inbred mouse strains to whole body X-Irradiation. Genetics 1957, 42:189-198.
19. Kallman R.F., Kohn H.I. The influence of strain on acute x-ray lethality in the mouse. I. LD50 and death rate studies. Radiation Research 1956, 5:309-317.
20. Kohn H.I., Kallman R.F. The influence of strain on acute X-ray lethality in the mouse. II. Recovery rate studies. Radiation Research 1957, 6:329-338.
21. Genetic and somatic effects of ionizing radiation 1986, vol. 16. UNSCEAR, 27-164.
22. Health risks from exposure to low levels of ionizing radiation 2006, BIER-VII.
23. Jacobson L.O., Marks E.K., Lorenz E. The hematological effects of ionizing radiations. Radiology 1949, 52:371-395.
24. Cronkite E.P., Brecher G. The protective effect of granulocytes in radiation injury. Annals of the New York Academy of Sciences 1955, 59:815-833.
25. Neta R., Oppenheim J.J. Cytokines in therapy of radiation injury. Blood 1988, 72:1093-1095.
26. Ramadori G., Sipe J.D., Dinarello C.A., Mizel S.B., Colten H.R. Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin 1 (IL-1) and purified human IL-1. The Journal of Experimental Medicine 1985, 162:930-942.
27. Gillis S., Mizel S.B. T-cell lymphoma model for the analysis of interleukin 1-mediated T-cell activation. Proceedings of Natural Academy of Sciences USA 1981, 8:1133-1137.
28. Park H.R., Jo S.K., Eom H.S. Chronic effects of single and fractionated gamma irradiation on an impairment of Th1-related immune response. International Journal of Radiation Biology 2011, 87:534-543.
29. Chamberlain R.E. Evaluation of live tularemia vaccine prepared in a chemically defined medium. Applied Microbiology 1965, 13:232-235.
30. Mara-Koosham G., Hutt J.A., Lyons C.R., Wu T.H. Antibodies contribute to effective vaccination against respiratory infection by Type A Francisella tularensis. Infection and Immunity 2011, 79:1770-1778.
31. Shen H., Harris G., Chen W., Sjostedt A., Ryden P., Conlan W. Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy. PLoS One 2010, 5:13349.
32. Twine S.M., Petit M.D., Fulton K.M., House R.V., Conlan J.W. Immunoproteomics analysis of the murine antibody response to vaccination with an improved Francisella tularensis live vaccine strain (LVS). PLoS One 2010, 5:e10000.
33. Cole L.E., Yang Y., Elkins K.L., Fernandez E.T., Qureshi N., Shlomchik M.J. Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge. Proceedings of Natural Academy of Sciences USA 2009, 106:4343-4348.
34. Ray H.J., Cong Y., Murthy A.K., Selby D.M., Klose K.E., Barker J.R. Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A. Clinical and Vaccine Immunology 2009, 16:444-452.
35. Savitt A.G., Mena-Taboada P., Monsalve G., Benach J.L. Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy. Clinical and Vaccine Immunology 2009, 16:414-422.
36. Havlasová J., Hernychová L., Brychta M., Hubálek M., Lenco J., Larsson P. Proteomic analysis of anti-Francisella tularensis LVS antibody response in murine model of tularemia. Proteomics 2005, 5:2090-2103.
37. Sjostedt A., North R.J., Conlan J.W. The requirement of tumour necrosis factor-alpha and interferon-gamma for the expression of protective immunity to secondary murine tularaemia depends on the size of the challenge innoculum. Microbiology 1996, 142:1369-1374.
38. Havlasová J., Hernychová L., Halada P., Pellantová V., Krejsek J., Stulík J. Mapping of immunoreactive antigens of Francisella tularensis live vaccine strain. Proteomics 2002, 2:857-867.
39. Kilmury S.L., Twine S.M. The Francisella tularensis proteome and its recognition by antibodies. Frontiers in Microbiology 2010, 1:143. Epub 2011 Jan 7. PubMed PMID:21687770; PubMed Central PMCID: PMC3109489.
40. Sanapala S., Yu J.J., Murthy A.K., Li W., Guentzel M.N., Chambers J.P. Perforin- and granzyme-mediated cytotoxic effector function are essential for protection against Francisella tularensis following vaccination by the defined F. tularensis subsp. novicida ΔfopC vaccine strain. Infection and Immunity 2012, 80:2177-2185.